Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis

NCT: NCT07680738 · COMPLETED

NCT IDNCT07680738
StatusCOMPLETED
Start Date2023-08-01
Completion2024-08-30
SponsorUniversidad de Almeria (OTHER)
First posted
Last updated

Brief Summary

Multiple sclerosis (MS) is a chronic, inflammatory and disabling disease of the Cnetral Nervous System characterized by relapsing and / or progressive somatosensory, motor and vestibular clinical manifestations. Moreover, fatigue, depression, anxiety, and cognitive impairment are also present in most MS patients. These symptoms substantially impact quality of life and often show limited response to conventional pharmacological treatment. Transcranial direct current stimulation (tDCS) is a non-invasive technique that applies a weak direct current to the scalp via surface electrodes, modulating cortical excitability in a polarity-dependent manner. The objective of this study is to evaluate the efficacy and safety of tDCS for fatigue, depression, anxiety, and cognitive performance in patients with relapsing or progressive MS.

Frequently Asked Questions

What is Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis?

Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis is a clinical trial registered under NCT07680738. Current status: COMPLETED.

What is the status of NCT07680738?

The current status of NCT07680738 (Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis) is: COMPLETED.

When did Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis start?

Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis started on 2023-08-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.